13 results about "PDX1" patented technology

A method for producing pancreatic endocrine cells, including introducing (B) or (D) below into cultured somatic cells to transdifferentiate into a population of pancreatic endocrine cells that include insulin-producing beta-cells: (B) a GLIS1 gene or one or more gene products thereof, a Neurogenin3 gene or one or more gene products thereof, and a Pdx1 gene or one or more gene products thereof; and (D) a GLIS1 gene or one or more gene products thereof, a Neurogenin3 gene or one or more gene products thereof, and a MafA gene or one or more gene products thereof. The GLIS1 gene includes the nucleotide sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The population of pancreatic endocrine cells are produced without undergoing an iPS cell stage.

Provided are: an expression vector with which it is possible to create, in vivo in an animal, an insulin-producing cell directly in a live body and to produce an animal having insulin-producing tissue by a simple treatment, and which is useful for medical research; an insulin production model animal; a method for producing the insulin production model animal; and an insulin production method using the insulin production model animal. This expression vector has, with respect to a Tet control expression regulatory vector having a TRE3G promotor region, the MafA gene and the Pdx1 gene inserted on the upstream of the TRE3G promotor, and the Neurogenin3 gene and the Glis1 gene or a mutated Glis1 gene inserted on the downstream of the TRE3G promotor. The present invention also pertains to an insulin production model animal, a method for producing the insulin production model animal, and an insulin production method using the insulin production model animal.

Methods are provided for generating pancreatic endocrine cells from pluripotent stem cells (PSCs) using epigenetic modifiers. A fusion protein comprising catalytically inactivated Cas9 (dCas9) and an embryonic ectoderm development (EED)-binding domain (EBdCas9) is used with guide RNAs (gRNAs) to target regulatory regions of transcriptional regulators including EOMES, PDX1, and NGN3. Sequential targeting of PDX1 and NGN3 promoters with EBdCas9 removes repressive H3K27me3 marks, increases activating H3K27ac modifications, and accelerates differentiation into insulin-producing β-cells. The methods significantly increase β-cell yields (~4-6 fold), reduce non-pancreatic lineage contaminants (CDX2+, SOX2+, enteroendocrine cells), enhance mitochondrial function, and produce glucose-responsive cells with superior functional maturation in vivo. The epigenetic interventions enforce pancreatic developmental fates while activating NGN3-dependent transcriptional programs necessary for endocrine cell differentiation, insulin secretion, and metabolic maturation. Cells and compositions produced by these methods are also provided.

The present disclosure relates to the development of methods for making β-cells from differentiated, multipotent or pluripotent stem cells by introducing and expressing a combination of transcription factors. The present disclosure also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes. In various embodiments, the combination of transcription factors is selected from a group consisting of: (a) Pax6, Ngn3, MafA; (b) Rfx6, Ngn3, MafA; (c) Pax6, Ngn3, Rfx6, MafA; (d) Nkx6.1, Pdx1, MafA; and (e) Pdx1, Pax6, Rfx6, Neurodi.

The invention discloses a pancreatic tissue specific expression recombinant adeno-associated virus vector and application thereof, and belongs to the technical field of biological medicine. Comprising the following steps: S1, cloning a pancreatic specific promoter: jointly using Ins2 and Pdx1 promoters to prepare a Pdx-1 / Ins2 promoter; performing serotype and capsid mutation optimization; s2, insertion of an exogenous gene expression cassette: cloning a target gene to the downstream of a Pdx-1 / Ins2 promoter to construct a'promoter-exogenous gene-polyadenylic acid signal 'expression unit; s3, regulation and control element integration: inserting an HS4 insulator sequence into two sides of an expression box, and adopting Gibson assembly to realize seamless connection; constructing an SIN structure: deleting a U5 region in ITR through site-specific mutagenesis or enzyme digestion, and verifying that no residual promoter activity exists; s4, virus packaging and purification: packaging rAAV particles by adopting an HEK293 cell three-plasmid co-transfection system; the three plasmids comprise a carrier plasmid, an auxiliary plasmid and a packaging plasmid; and determining the purity after purification.

The invention belongs to the technical field of biology, and particularly relates to a method for efficiently synthesizing vitamin B6 by using bacillus subtilis. The method for synthesizing the vitamin B6 by using the bacillus subtilis comprises the following steps: PDX1, PDX2 and PLPP are simultaneously expressed in the bacillus subtilis, PDX1 and PDX2 are two subunits of phosphopyridoxal synthetase, and the amino acid sequences of PDX1 and PDX2 are shown as SEQ ID NO: 4 and SEQ ID NO: 5; pLPP is phosphopyridoxal phosphatase, and the amino acid sequence of PLPP is shown as SEQ ID NO: 6. The method realizes efficient production of vitamin B6 in bacillus subtilis, and has wide application prospects in the fields of food additives and pharmaceutical industry.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

To provide a device and method for grafting a cell such as a pancreatic endoderm cell to a host.SOLUTION: A cell delivery device includes a nonwoven fabric outside a cell excluding membrane, and can drill the nonwoven fabric and / or the cell excluding membrane. Treatment of a host by immune suppression reagent is required in order to suppress allograft rejection by drilling of the device, and does not impair maturation or function of a grafted pancreatic endoderm cell.SELECTED DRAWING: Figure 1A

The invention discloses a methylation marker combination for colorectal cancer detection, a corresponding primer probe combination, a kit and application thereof. The colorectal cancer related methylation marker combination comprises a CpG methylation site cg03414318 of a DLGAP4 gene, a CpG methylation site cg02002231 of an FGF5 gene, and a CpG methylation site cg26299169 of a PDX1 gene, and the colorectal cancer related methylation marker combination is a colorectal cancer related methylation marker combination. The methylation levels of the three sites in colorectal cancer tissues and normal tissues are remarkably different, and the methylation levels of the DLGAP4 and FGF5 sites are related to colorectal cancer staging, so that the DLGAP4 and FGF5 sites can be used as high-specificity markers for colorectal cancer early screening. The primer probe combination for detecting the marker combination comprises a specific upstream primer, a downstream primer and a probe aiming at each marker. The kit comprises a primer probe combination, and also comprises a positive control, a negative control and a quality control reagent. Three-site combined detection is adopted, the detection sensitivity in a colorectal cancer excrement sample reaches 94% or above, the specificity reaches up to 100%, and a high-precision solution is provided for colorectal cancer noninvasive early screening.

The invention relates to the technical field of gene engineering, and particularly discloses a toxoplasma gondii Me49 BFD2 PDX1 strain as well as a construction method and application thereof, and the toxoplasma gondii Me49 BFD2 PDX1 strain is obtained by knocking out a PDX1 gene in a Me49 BFD2 strain through a gene editing means. The toxoplasma gondii Me49 BFD2 PDX1 strain tachyzoite provided by the invention is used for inhibiting the growth of tumor cells and reducing the volume and the mass of tumors after being inactivated.

Methods are disclosed for treating a subject with type 2 diabetes. The methods include administering to the subject a therapeutically effective amount of a vector including an insulin promoter operably linked to a nucleic acid molecule encoding heterologous Pancreas duodenal homeobox protein (Pdx) 1 and MafA. In some embodiments, the vector does not encode Neurogenin 3 (Ngn3) and wherein the subject is not administered any other nucleic acid encoding Ngn3. The vector can be administered intraductally into a pancreatic duct of the subject. Compositions are disclosed that include a) a viral vector comprising an insulin promoter operably linked to a nucleic acid molecule encoding Pdx1 and a nucleic acid encoding MafA, wherein the vector does not encode Ngn3; b) a buffer; and c) a contrast dye for endoscopic retrograde cholangiopancreatography. These compositions are of use in any of the methods disclosed herein, and can be used to the improve hyperglucagonemia, insulin sensitivity, and / or glucose homeostasis in the subject.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

The present invention relates to a peptide having anti-obesity and anti-diabetes activities and uses thereof. The peptide of the present invention increases the expression of insulin genes and genes of PDX1 and GLP1R involved in insulin secretion, increases the secretion of insulin itself, and increases the expression levels of phospho-CREB and POMC factors associated with satiety signaling. In addition, the peptide of the present invention exhibits anti-obesity activity. Therefore, the peptide of the present invention can be used for treating, preventing, and alleviating obesity or diabetes, and can be advantageously used for lowering blood glucose levels of a person in need of blood glucose control.